These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
194 related articles for article (PubMed ID: 35190544)
21. Long-term Efficacy of Safinamide on Parkinson's Disease Chronic Pain. Cattaneo C; Kulisevsky J; Tubazio V; Castellani P Adv Ther; 2018 Apr; 35(4):515-522. PubMed ID: 29542008 [TBL] [Abstract][Full Text] [Related]
22. Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations. Borgohain R; Szasz J; Stanzione P; Meshram C; Bhatt M; Chirilineau D; Stocchi F; Lucini V; Giuliani R; Forrest E; Rice P; Anand R; Mov Disord; 2014 Feb; 29(2):229-37. PubMed ID: 24323641 [TBL] [Abstract][Full Text] [Related]
23. Characteristics of wearing-off and motor symptoms improved by safinamide adjunct therapy in patients with Parkinson's disease: A post hoc analysis of a Japanese phase 2/3 study. Nomoto M; Ishida T; Koebis M; Kamei T; Suzuki I; Hattori N; Tsuboi Y J Neurol Sci; 2022 Mar; 434():120083. PubMed ID: 35007919 [TBL] [Abstract][Full Text] [Related]
24. Effects of Safinamide on Pain in Fluctuating Parkinson's Disease Patients: A Post-Hoc Analysis. Cattaneo C; Barone P; Bonizzoni E; Sardina M J Parkinsons Dis; 2017; 7(1):95-101. PubMed ID: 27802242 [TBL] [Abstract][Full Text] [Related]
25. [Effectiveness and safety of safinamide as add-on to levodopa in patients with parkinson's disease: non-interventional study]. Jost WH; Kupsch A; Mengs J; Delf M; Bosse D Fortschr Neurol Psychiatr; 2018 Oct; 86(10):624-634. PubMed ID: 30142650 [TBL] [Abstract][Full Text] [Related]
26. Long-Term Effects of Safinamide on Mood Fluctuations in Parkinson's Disease. Cattaneo C; Müller T; Bonizzoni E; Lazzeri G; Kottakis I; Keywood C J Parkinsons Dis; 2017; 7(4):629-634. PubMed ID: 28777756 [TBL] [Abstract][Full Text] [Related]
27. [Safinamide Mesilate (Equfina Koebisu M; Ishida T Nihon Yakurigaku Zasshi; 2020; 155(4):269-276. PubMed ID: 32612042 [TBL] [Abstract][Full Text] [Related]
28. Efficacy of safinamide on non-motor symptoms in a cohort of patients affected by idiopathic Parkinson's disease. Bianchi MLE; Riboldazzi G; Mauri M; Versino M Neurol Sci; 2019 Feb; 40(2):275-279. PubMed ID: 30382437 [TBL] [Abstract][Full Text] [Related]
29. Sustained response in early responders to safinamide in patients with Parkinson's disease and motor fluctuations: A Bhidayasiri R; Koebis M; Kamei T; Ishida T; Suzuki I; Cho JW; Wu SL Front Neurol; 2023; 14():1147008. PubMed ID: 37051060 [TBL] [Abstract][Full Text] [Related]
30. Safinamide for symptoms of Parkinson's disease. Müller T Drugs Today (Barc); 2015 Nov; 51(11):653-9. PubMed ID: 26744740 [TBL] [Abstract][Full Text] [Related]
31. Impact of SAfinamide on Depressive Symptoms in Parkinson's Disease Patients (SADness-PD Study): A Multicenter Retrospective Study. Peña E; Borrué C; Mata M; Martínez-Castrillo JC; Alonso-Canovas A; Chico JL; López-Manzanares L; Llanero M; Herreros-Rodríguez J; Esquivel A; Maycas-Cepeda T; Ruíz-Huete C Brain Sci; 2021 Feb; 11(2):. PubMed ID: 33668408 [TBL] [Abstract][Full Text] [Related]
36. The Effects of Safinamide Adjunct Therapy on Depression and Apathy in Patients With Parkinson's Disease: Hattori N; Kogo Y; Koebis M; Ishida T; Suzuki I; Tsuboi Y; Nomoto M Front Neurol; 2021; 12():752632. PubMed ID: 35222225 [TBL] [Abstract][Full Text] [Related]
37. Emerging approaches in Parkinson's disease - adjunctive role of safinamide. Müller T Ther Clin Risk Manag; 2016; 12():1151-60. PubMed ID: 27536120 [TBL] [Abstract][Full Text] [Related]
38. Noninvasive options for 'wearing-off' in Parkinson's disease: a clinical consensus from a panel of UK Parkinson's disease specialists. Fackrell R; Carroll CB; Grosset DG; Mohamed B; Reddy P; Parry M; Chaudhuri KR; Foltynie T Neurodegener Dis Manag; 2018 Oct; 8(5):349-360. PubMed ID: 29975112 [TBL] [Abstract][Full Text] [Related]
39. Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson's disease: a multi-country Delphi-panel approach. Antonini A; Stoessl AJ; Kleinman LS; Skalicky AM; Marshall TS; Sail KR; Onuk K; Odin PLA Curr Med Res Opin; 2018 Dec; 34(12):2063-2073. PubMed ID: 30016901 [TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of safinamide as an add-on therapy to L-DOPA for patients with Parkinson's disease: A randomized, double-blind, placebo-controlled, phase II/III study. Hattori N; Tsuboi Y; Yamamoto A; Sasagawa Y; Nomoto M; Parkinsonism Relat Disord; 2020 Jun; 75():17-23. PubMed ID: 32446176 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]